| Document |
Document Title |
|
WO/2023/051793A1 |
Disclosed are a compound as an inhibitor of complement factor D, and a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereo...
|
|
WO/2023/046664A1 |
The invention relates to novel compounds of the general formula (l-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2023/049860A1 |
The present disclosure relates generally to dis-arming immune cell product sensitivity to androgens. Provided herein are methods, systems, and compositions for disarming androgen receptor (AR) activity in immune cells, for instance in th...
|
|
WO/2023/045005A1 |
The present invention relates to a method for preparing total glucosides of Paeonia. The method comprises the following steps: 1) extraction: taking decoction pieces of radix paeoniae alba, extracting with ethanol, and filtering an extra...
|
|
WO/2023/049121A1 |
Analysis of gene expression in allograft biopsies is provided for diagnosis and/or treatment of antibody rejection. We chose over a hundred candidate genes to evaluate their association with allograft pathology by real-time quantitative ...
|
|
WO/2023/049787A1 |
The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease, and methods of identifying subjects having an increased risk of developing a kidney disease.
|
|
WO/2023/046046A1 |
Provided is a hydrogenation synthesis method for preparing a pyrazinecarboxylic acid derivative as a fluorescent tracer, in particular, provided is a method for preparing 3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamo
yl}py...
|
|
WO/2023/045360A1 |
The present invention relates to the technical field of drug synthesis. Disclosed are a crystal form of a macrocyclic compound, and a preparation method therefor and the use thereof. The macrocyclic compound is (6R, 16R)-9-fluoro-16-meth...
|
|
WO/2023/048277A1 |
Provided is a group 2 innate lymphoid cell growth inhibitor containing MAIT cells.
|
|
WO/2023/049917A1 |
The present disclosure encompasses novel anti- TGFβ1,2,3 antibodies and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies and/or nucleotide of the 5 invention for the treatment and/or prevent...
|
|
WO/2023/039947A1 |
Disclosed are a pharmaceutical composition containing cefoperazone sodium and tazobactam sodium, and an application thereof. In the pharmaceutical composition, the weight ratio of cefoperazone sodium to tazobactam sodium is 6:1. In the t...
|
|
WO/2023/044326A1 |
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl
)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of usin...
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/042996A1 |
The present invention relates to a pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutica...
|
|
WO/2023/043024A1 |
The present invention relates to a pharmaceutical composition for preventing or treating Interstitial Fibrosis and Tubular Atrophy (IFTA) acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a...
|
|
WO/2023/043473A1 |
A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human TGF-β. In certain aspects, the disclosed invention is based, on engineering of a heterodimer...
|
|
WO/2023/039500A1 |
The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI | and fecal incontinence [FI] due to weakness...
|
|
WO/2023/039063A1 |
The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,
2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
|
|
WO/2023/036312A1 |
A halogen-substituted pyridazinone compound and an application thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/036707A1 |
Substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines, salts thereof and their use as herbicidally active substances. The present invention relates to substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines of the general formula (I) or salt...
|
|
WO/2023/038068A1 |
The present invention provides a pharmaceutical composition for preventing or treating interstitial cystitis/bladder pain syndrome, the pharmaceutical composition containing an inhibitor against at least one type of integrin selected fro...
|
|
WO/2023/036250A1 |
The present invention provides a drug used for treating prostatitis or prostatic hyperplasia. The drug comprises sulforaphane or a plant extract that contains sulforaphane. The present invention provides sulforaphane as an effective comp...
|
|
WO/2023/036203A1 |
A Cs-4 fermented mycelium heteropolysaccharide, a preparation method therefor and a use thereof. The polysaccharide structure is shown below, where N is selected from 6-104. The polysaccharide can be used for preventing or treating chron...
|
|
WO/2023/036300A1 |
DBC1 regulating cell senescence and a use thereof. A use of a DBC1 promoter in the preparation of a drug for preventing or treating senescence-related diseases or disorders. A use of ML216 in the preparation of a drug for preventing or t...
|
|
WO/2023/039604A1 |
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
|
|
WO/2023/039392A1 |
Methods and materials for assessing therapeutic efficacy with particulate guanylyl cyclase (pGC) receptor stimulators are provided herein. Also provided herein are methods and materials for administering pGC receptor stimulators to mamma...
|
|
WO/2023/037868A1 |
It is found that fibroblasts can suppress kidney fibrosis and can recover the function of the kidney in a rat model with a kidney disease. As a result, a pharmaceutical composition for treating a kidney disease which contains fibroblasts...
|
|
WO/2023/030492A1 |
An EP4 antagonist represented by formula I, which specifically comprises a crystal form thereof, a pharmaceutically acceptable salt or crystal form thereof, a preparation method therefor, a composition containing same, and a medical use ...
|
|
WO/2023/033137A1 |
One of the purposes of the present invention is to provide a novel method for producing a kidney organoid. Provided is a method for producing a kidney organoid, the method being characterized by including culturing an initial kidney or...
|
|
WO/2023/032955A1 |
In one embodiment, the present invention provides an antibody specifically binding to human GH, or an antigen-binding fragment thereof. In one embodiment, the present invention pertains to an antibody specifically binding to human GH, or...
|
|
WO/2023/033174A1 |
This phytin has improved solubility in water. The present application provides a phytin that contains calcium and/or magnesium at a specific mole ratio with respect to phytic acid.
|
|
WO/2023/032987A1 |
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...
|
|
WO/2023/030470A1 |
The present invention belongs to the technical field of chemical medicine, and provided are an endothelin A (ETA) receptor antagonist compound, a preparation method therefor and a medical use thereof.
|
|
WO/2023/031397A1 |
The invention refers to Fc silenced anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains, a...
|
|
WO/2023/025277A1 |
Provided are an aromatic ring-containing biological antagonist as represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the prepa...
|
|
WO/2023/025266A1 |
The present application relates to a pharmaceutical composition, comprising: sulbactam or a pharmaceutically acceptable salt thereof, and avibactam or a pharmaceutically acceptable salt thereof, the unit dose ratio of the sulbactam or th...
|
|
WO/2023/026185A1 |
The present invention relates to methods of treating renal cystic disease and/or cardiorenal syndrome by administrating certain compounds that modulate the activity of the beta-3 adrenergic receptor.
|
|
WO/2023/025241A1 |
Disclosed are a novel precursor compound of abiraterone, and a preparation method therefor and a use thereof. The structure of the compound is shown in formula I. The present invention also provides a preparation method for the compound ...
|
|
WO/2023/025271A1 |
A crystal form of a pyrazine derivative and a preparation method therefor, specifically relating to a crystal form, in particular crystal forms A-G of 3,6-diamino-2,5-bis{N-[(1R)-1-carboxyl-2-hydroxyethyl]carbam
oyl}pyrazine (compound I)...
|
|
WO/2023/020486A1 |
Provided are a receptor-interacting protein-1 ("RIP1") kinase inhibitor compound as shown in formula (I), or a stereoisomer, tautomer, deuterated substance, nitrogen oxide, solvate or pharmaceutically acceptable salt thereof, a pharmaceu...
|
|
WO/2023/023465A1 |
Disclosed herein are antibodies or antigen binding fragments thereof that bind vascular endothelial growth factor receptor 1 (VEGFR1), polynucleotides, vectors, host cells and methods of treating chronic kidney disease using the same.
|
|
WO/2023/021353A1 |
The present invention relates to an in vitro and/or ex vivo method for the prognosis of prostate cancer in a subject and/or for determining if a subject suffering from prostate cancer is responsive to a therapeutic treatment, as well as ...
|
|
WO/2023/023473A1 |
This disclosure provides methods of treating chronic kidney disease (CKD) in a subject using momelotinib (MMB). Also provided are methods of preventing or treating anemia or other diseases or conditions associated with kidney disease in ...
|
|
WO/2023/022473A1 |
The present invention relates to a pharmaceutical composition comprising pineal gland hormone-treated mesenchymal stem cell-derived extracellular vesicles as an active ingredient. The extracellular vesicles extracted from pineal gland ho...
|
|
WO/2023/023459A1 |
A dietary supplement composition includes a shelf stable, supercritical CO2 fluid extracted, enhanced lipidosterolic extract of Serenoa repens (LSESr) having about an enrichment of lauric, myristic, oleic and linoleic free fatty acids to...
|
|
WO/2023/020135A1 |
Disclosed in the present invention are an abiraterone derivative and a preparation method therefor. The abiraterone derivative provided by the present invention shows relatively few abdominal distension phenomena with respect to abirater...
|
|
WO/2023/020566A1 |
Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the ...
|
|
WO/2023/020156A1 |
The present invention relates to a P2X3 receptor-selective modulator of an imidazopyridine derivative, and specifically to a compound represented by formula I and a racemate, a stereoisomer, a tautomer, an isotopic label, a solvate, a po...
|
|
WO/2023/016483A1 |
The present application relates to a method for preparing a pyrazine derivative as a fluorescent tracer, and specifically relates to a method for preparing 3,6-diamino-2,5-bis{N-(1R)-1-carboxy-2-hydroxyethyl]carbamoy
l}pyrazine, an inter...
|
|
WO/2023/018347A1 |
The invention relates to the field of medicine and veterinary medicine, in particular to a pharmaceutical composition for improving the filtering function of kidneys. A pharmaceutical composition for improving the filtering function o...
|
